This archive contains the following articles listed by volume, issue and page number:
 |
|
|
PEDIATRICS RELATED ARTICLES |
Title (Click for Details) |
Vol/Issue |
Page |
Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested |
Vol. 24 No. 5 |
408 |
Sorafenib Capsules for Pediatric Use |
Vol. 23 No. 5 |
411 |
Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients |
Vol. 23 No. 4 |
324 |
Methotrexate 2-mg/mL Oral Solution |
Vol. 23 No. 3 |
235 |
Basics of Compounding: Standardization of Compounded Medications |
Vol. 23 No. 1 |
35 |
PreScription: Standardized Concentrations: Pro or Con? |
Vol. 22 No. 6 |
444 |
Current Trends and Emerging Priorities in Compounded Preparations for Children |
Vol. 22 No. 5 |
358 |
Stability of Dalteparin 1,000 Unit/mL in 0.9% Sodium Chloride for Injection in Polypropylene Syringes |
Vol. 21 No. 5 |
426 |
Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas |
Vol. 21 No. 4 |
282 |
Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules |
Vol. 21 No. 2 |
171 |
Case Report: Pediatric Scar Management After Open-heart Surgery |
Vol. 20 No. 4 |
277 |
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children |
Vol. 20 No. 3 |
247 |
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children |
Vol. 20 No. 3 |
257 |
Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis |
Vol. 20 No. 1 |
6 |
Practicing Your Compounding Skills Outsides of Your Pharmacy's Walls |
Vol. 19 No. 3 |
205 |
L-Cysteine Hydrochloride 50-mg/mL Injection |
Vol. 19 No. 2 |
146 |
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition |
Vol. 18 No. 5 |
427 |
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013 |
Vol. 18 No. 1 |
6 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 |
Vol. 17 No. 6 |
446 |
Preventing Medication Errors with Nimodipine by Compounding Proper Dosage Forms |
Vol. 17 No. 5 |
364 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1 |
Vol. 17 No. 5 |
388 |
Indomethacin 1-mg/mL Injection |
Vol. 17 No. 5 |
419 |
Pattern of Extemporaneous Prescriptions and Preparations in a Tertiary Health Institution: A Five-year Assessment |
Vol. 17 No. 5 |
432 |
Pediatric Health Care: An Introduction |
Vol. 17 No. 1 |
6 |
A Concise Discussion of Headache Types, Part 3: Migraine |
Vol. 16 No. 4 |
270 |
A Retrospective Observational Case Series Analysis of the Usage of Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Alabama Patients |
Vol. 15 No. 6 |
446 |
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers |
Vol. 15 No. 6 |
458 |
Diaper Rash Relief: Common Sense Remedies and Treatments |
Vol. 15 No. 6 |
464 |
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride |
Vol. 15 No. 5 |
358 |
Updated Case Report: The Use of Topical Concentrated Capsaicin Cream to Treat Erythromelalgia in a Pediatric Patient |
Vol. 15 No. 5 |
386 |
Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient |
Vol. 15 No. 4 |
316 |
Case Report: The Use of Topical Concentrated Capsaicin Cream to Treat Erythromelalgia in a Pediatric Patient |
Vol. 15 No. 3 |
194 |
Extemporaneous Preparation of Sertraline Cream for Transdermal Administration |
Vol. 15 No. 3 |
200 |
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease |
Vol. 15 No. 2 |
124 |
Acetylcysteine 1% or 10% Oral Solution |
Vol. 15 No. 2 |
156 |
Glutathione 25% in Pluronic Lecithin Organogel |
Vol. 14 No. 6 |
518 |
Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together |
Vol. 14 No. 4 |
270 |
Calculating Carbohydrate Content of Compounded Medications for Patients on a Ketogenic Diet |
Vol. 14 No. 1 |
21 |
Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis |
Vol. 14 No. 1 |
40 |
When Traditional Medicine Fails |
Vol. 14 No. 1 |
6 |
Calculations |
Vol. 14 No. 1 |
58 |
Emanuel Butt Paste |
Vol. 13 No. 5 |
431 |
Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding |
Vol. 13 No. 4 |
314 |
Compounding Naltrexone for the Treatment of Autism |
Vol. 13 No. 4 |
296 |
Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report |
Vol. 13 No. 3 |
220 |
Compounding for Pediatric Patients: Case Reports and Formulations |
Vol. 13 No. 1 |
6 |
Evaluation of Dosage Form Information Provided in Pediatric Drug Trial Reports |
Vol. 13 No. 1 |
14 |
Calculations |
Vol. 13 No. 1 |
63 |
Acetaminophen, Pseudoephedrine Hydrochloride, and Chlorpheniramine Maleate Powder Packets |
Vol. 13 No. 1 |
64 |
Amphotericin B, Chloramphenicol Palmitate, Hydrocortisone, and Sulfanilamide Otic Powder |
Vol. 13 No. 1 |
65 |
Diaper Rash Cream with Miconazole |
Vol. 13 No. 1 |
68 |
Diphenhydramine Hydrochloride 25-mg Gelatin Troches |
Vol. 13 No. 1 |
69 |
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada |
Vol. 12 No. 4 |
365 |
Benzyl Benzoate Lotion |
Vol. 12 No. 3 |
261 |
Valsartan 4-mg/mL Oral Liquid |
Vol. 12 No. 3 |
269 |
Trimethoprim 10-mg/mL Oral Suspension |
Vol. 12 No. 1 |
73 |
Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2 |
Vol. 11 No. 3 |
220 |
Methylphenidate 1-mg/mL Oral Liquid |
Vol. 11 No. 3 |
249 |
Challenges of Compounding for Patients on the Ketogenic Diet |
Vol. 11 No. 2 |
116 |
Ranitidine Hydrochloride 15-mg/mL Oral Liquid |
Vol. 11 No. 2 |
161 |
Need for Appropriate Formulations for Children: The National Institute of Child Health and Human DevelopmentāPediatric Formulations Initiative, Part 1 |
Vol. 11 No. 1 |
5 |
Principles of Pediatric Palliative Care and Pain Control |
Vol. 11 No. 1 |
10 |
Pediatric Oral Formulations: A Continual Challenge |
Vol. 11 No. 1 |
17 |
Sevelamer Suspension in Children with End-Stage Renal Disease |
Vol. 11 No. 1 |
20 |
Case Report: Cocktail Dosing in a Premature Infant with a History of Cholestasis |
Vol. 11 No. 1 |
26 |
Case Report: Treatment of Labial Adhesions in a Child |
Vol. 11 No. 1 |
27 |
Calculations |
Vol. 11 No. 1 |
68 |
Caffeine Citrate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
69 |
Carbidopa 1.25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
70 |
Clonidine Hydrochloride 0.1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
71 |
Methyldopa 25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
75 |
Metolazone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
76 |
Prednisone 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
77 |
Prednisolone Sodium Phosphate 10-mg/mL Oral Liquid |
Vol. 11 No. 1 |
78 |
Nitrazepam 1-mg/mL Oral Liquid |
Vol. 10 No. 5 |
388 |
Oral Rehydration Salts (World Health Organization/United Nations Children's Fund) |
Vol. 10 No. 5 |
390 |
Adderall 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
299 |
Lisinopril 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
302 |
Nifedipine 4-mg/mL Oral Liquid |
Vol. 10 No. 4 |
303 |
Propranolol Hydrochloride 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
304 |
Propylthiouracil 5-mg/mL Oral Liquid |
Vol. 10 No. 1 |
67 |
Prescription: Pediatric Formulation Initiatives |
Vol. 9 No. 6 |
410 |
Unlocking Autism: Is Compounding the Key? |
Vol. 9 No. 6 |
413 |
Compounding for a Pediatric Hospital |
Vol. 9 No. 6 |
423 |
Wiping Out Diaper Rash |
Vol. 9 No. 6 |
433 |
Pediatric Oral Liquid Preparations |
Vol. 9 No. 6 |
437 |
Basics of Compounding for Pediatric Patients: Commonly Prescribed Oral Liquid Formulations, Vehicles, and Stock Solutions |
Vol. 9 No. 6 |
456 |
PostScription: Compounding Pharmacies and the Successful Treatment of Autism |
Vol. 9 No. 6 |
487 |
Calculations |
Vol. 9 No. 1 |
57 |
Stability of an Extemporaneously Compounded Propylthiouracil Suspension |
Vol. 9 No. 1 |
82 |
A Need for Propylene Glycol-Free Ascorbic Acid Oral Liquid |
Vol. 8 No. 6 |
458 |
Domperidone in Lactation: Use as a Galactagogue |
Vol. 8 No. 5 |
329 |
Head to Toe Solutions: A Quick Review of Current Therapies |
Vol. 8 No. 5 |
345 |
Book and Literature Reviews |
Vol. 8 No. 4 |
244 |
Gag Tablet Lollipops |
Vol. 8 No. 3 |
184 |
Amiodarone HCl 5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
214 |
Atenolol 2-mg/mL Oral Liquid |
Vol. 8 No. 3 |
215 |
Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
218 |
Flucytosine 10-mg/mL Oral Liquid |
Vol. 8 No. 2 |
134 |
Griseofulvin 25-mg/mL Oral Liquid |
Vol. 8 No. 2 |
135 |
Stomatitis Mouthwash |
Vol. 8 No. 2 |
140 |
Tacrolimus 0.5-mg/mL Oral Liquid |
Vol. 8 No. 2 |
141 |
Tiagabine 1-mg/mL Oral Liquid |
Vol. 8 No. 2 |
142 |
Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension |
Vol. 7 No. 6 |
485 |
Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
Ursodiol 150-mg Capsules |
Vol. 7 No. 5 |
382 |
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
Pediatric Dermatitis |
Vol. 6 No. 6 |
419 |
Excerpts from and Reviews of Current Published Literature: Pediatric Medications |
Vol. 6 No. 6 |
423 |
Book Reviews: Compounding for Pediatric Patients |
Vol. 6 No. 6 |
424 |
Caffeine and Sodium Benzoate 250-mg/mL Injection |
Vol. 6 No. 6 |
449 |
Dimenhydrinate 50-mg/mL Injection |
Vol. 6 No. 6 |
451 |
Erythromycin 400-mg/mL and Rifampin 50-mg/mL Oral Liquid |
Vol. 6 No. 5 |
367 |
Topical Secretin for the Treatment of Autism |
Vol. 5 No. 6 |
436 |
Basics of Compounding: Suspensions |
Vol. 5 No. 4 |
294 |
Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Sugar-Free Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Spironolactone Oral Suspension 2-mg/mL |
Vol. 5 No. 4 |
297 |
Progesterone Oral Suspension 40-mg/mL |
Vol. 5 No. 4 |
297 |
Xanthan Gum Oral Suspension Vehicle 0.3% |
Vol. 5 No. 4 |
297 |
Pediatric Preoperative Cocktail Injection |
Vol. 5 No. 4 |
306 |
The Basics of Compounding Emulsions, Part 2 |
Vol. 5 No. 3 |
198 |
The Basics of Compounding Emulsions, Part 1 |
Vol. 5 No. 2 |
120 |
Pediatric Compounding: Coloring Outside the Lines |
Vol. 5 No. 1 |
6 |
Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients |
Vol. 5 No. 1 |
9 |
Flavoring: Compounding a Treat |
Vol. 5 No. 1 |
13 |
Autism in Children |
Vol. 5 No. 1 |
18 |
Methylphenidate in the Treatment of Attention Deficit Disorders |
Vol. 5 No. 1 |
21 |
A Pediatric Miscellany: Excerpts from and Reviews of Current Published Literature |
Vol. 5 No. 1 |
23 |
Compounding in History: Pediatric Considerations |
Vol. 5 No. 1 |
30 |
Electrolyte and Rehydration Powder for Solution-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
Cholestyramine 6.5% Ointment |
Vol. 5 No. 1 |
42 |
Ivermectin 0.8% Creme Rinse |
Vol. 5 No. 1 |
43 |
Lidocaine HCl 4%-Epinephrine HCl 0.05%-Tetracaine HCl 0.5% Topical Gel |
Vol. 5 No. 1 |
44 |
Lorazepam 1-mg Chewable Gummy Gels |
Vol. 5 No. 1 |
45 |
Metronidazole Benzoate 400-mg/5-mL Oral Suspension |
Vol. 5 No. 1 |
46 |
Natural Head Lice Repellant Spray |
Vol. 5 No. 1 |
48 |
Niacinamide 4% Acne Gel |
Vol. 5 No. 1 |
49 |
Promethazine HCl 50-mg/mL in PLO Gel |
Vol. 5 No. 1 |
51 |
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations |
Vol. 4 No. 4 |
289 |
Ondansetron HCl 8-mg/mL in PLO |
Vol. 4 No. 4 |
305 |
Compounding Ear, Nose and Throat Preparations |
Vol. 4 No. 3 |
164 |
Xylitol in the Prevention of Otitis Media |
Vol. 4 No. 3 |
171 |
Sildenafil 0.2% Otic Drops |
Vol. 4 No. 3 |
175 |
Amphotericin B 100-mg Troches |
Vol. 4 No. 3 |
208 |
Nystatin 250,000-Unit and/or Tetracaine HCl 0.025% Popsicles |
Vol. 4 No. 3 |
214 |
Basics of Compounding: Compounding Solutions |
Vol. 4 No. 2 |
122 |
Sugar-Free Suspension Structured Vehicle, USP |
Vol. 4 No. 2 |
136 |
The Basics of Compounding: Compounding Hard, Soft and Chewable Troches/Lozenges/Drops |
Vol. 3 No. 6 |
461 |
Linguet Base (Soft Lozenge) |
Vol. 3 No. 6 |
462 |
Sorbitol Based Hard Lozenges |
Vol. 3 No. 6 |
462 |
Sucrose Based Hard Lozenges |
Vol. 3 No. 6 |
462 |
Polyethylene Glycol (PEG) Troches (Soft Lozenges) |
Vol. 3 No. 6 |
463 |
Polyethylene Glycol (PEG) Troches with Suspending Agent (Soft Lozenges) |
Vol. 3 No. 6 |
463 |
Chewable Lozenges |
Vol. 3 No. 6 |
464 |
Methotrexate 2.5-mg/5-mL Oral Liquid |
Vol. 3 No. 6 |
474 |
Extemporaneous Formulations in Pediatric Patients |
Vol. 3 No. 4 |
274 |
Analysis of Extemporaneous Alprostadil Formulations |
Vol. 3 No. 2 |
148 |
Oral Ulceration Mouthwash |
Vol. 3 No. 1 |
10 |
Alternatives for the Lactose-Intolerant Patient |
Vol. 2 No. 6 |
412 |
Pediatric Central Parenteral Nutrition Solution |
Vol. 2 No. 5 |
368 |
Pediatric Central Parenteral Nutrition Solution with Heparin |
Vol. 2 No. 5 |
369 |
Pediatric Peripheral Parenteral Nutrition Solution |
Vol. 2 No. 5 |
370 |
Malathion Topical Lotion: Therapy for Resistant Head Lice |
Vol. 2 No. 4 |
268 |
Compatibility and Stability of Ranitidine Hydrochloride with Six Cephalosporins During Simulated Y-Site Administration |
Vol. 2 No. 4 |
318 |
Tetracaine HCl 1%, Epinephrine HCl 0.025% and Cocaine HCl 4% Topical Solution and Gel |
Vol. 2 No. 2 |
159 |
Vehicles for Compounding Oral Liquids: Some Practical Considerations |
Vol. 2 No. 2 |
160 |
Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane |
Vol. 2 No. 1 |
83 |
Ketoconazole 20-mg/mL Oral Liquid |
Vol. 1 No. 6 |
414 |
Baclofen 10-mg/mL Oral Liquid |
Vol. 1 No. 5 |
321 |
Captopril 0.75-mg/mL Oral Liquid |
Vol. 1 No. 5 |
322 |
Diltiazem HCl 12-mg/mL Oral Suspension |
Vol. 1 No. 5 |
323 |
Stability of Bethanechol Chloride Oral Liquid Dosage Forms |
Vol. 1 No. 4 |
278 |
Allopurinol 20-mg/mL Oral Liquid |
Vol. 1 No. 3 |
174 |
Dipyridamole 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
176 |
Labetalol HCl 40-mg/mL Oral Liquid |
Vol. 1 No. 3 |
179 |
Metoprolol Tartrate 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
180 |
Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid |
Vol. 1 No. 3 |
183 |
Spironolactone 25-mg/mL Oral Liquid |
Vol. 1 No. 3 |
184 |
Verapamil HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 3 |
188 |
The Formulation Development and Stability of Spironolactone Suspension |
Vol. 1 No. 3 |
195 |
The Formulation Development and Stability of Metronidazole Suspension |
Vol. 1 No. 3 |
200 |
Metronidazole 15-mg/mL Suspension |
Vol. 1 No. 3 |
202 |
Compounding for the Pediatric Patient |
Vol. 1 No. 2 |
84 |
Attention Deficit Hyperactivity Disorder |
Vol. 1 No. 2 |
87 |
Flavors and Flavoring |
Vol. 1 No. 2 |
90 |
Compounded Suppositories and Pharmaceutical Care |
Vol. 1 No. 2 |
93 |
Acetazolamide 25-mg/mL Oral Liquid |
Vol. 1 No. 2 |
101 |
Azathioprine 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
102 |
Flecainide Acetate 20-mg/mL Oral Liquid |
Vol. 1 No. 2 |
103 |
Methylcellulose 1% to 5% Solutions |
Vol. 1 No. 2 |
104 |
Methylcellulose Oral-Liquid Vehicles |
Vol. 1 No. 2 |
105 |
Pediatric Chewable Gummy Gel Base |
Vol. 1 No. 2 |
106 |
Pediatric Chocolate Troche Base |
Vol. 1 No. 2 |
106 |
Pediatric Chewable Gummy Gels |
Vol. 1 No. 2 |
107 |
Pediatric Chocolate Troche |
Vol. 1 No. 2 |
108 |
Nystatin Popsicles |
Vol. 1 No. 2 |
109 |
Procainamide HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
110 |
Syrup NF |
Vol. 1 No. 2 |
111 |
Tetracaine 20-mg Lollipops |
Vol. 1 No. 2 |
112 |
Tetracycline Compound Troche |
Vol. 1 No. 2 |
113 |
Xanthan Gum Suspension Vehicle (0.2% to 0.5%) |
Vol. 1 No. 2 |
114 |
Omeprazole (Prilosec) in the Atypical Patient, Administration of |
Vol. 1 No. 1 |
13 |
HDDM Hard Troche |
Vol. 1 No. 1 |
29 |
HDDM Soft Troche |
Vol. 1 No. 1 |
30 |
HDDM Sugar Troche |
Vol. 1 No. 1 |
30 |
Metoclophen Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Metoclophen-Modified Nausea Suppositories |
Vol. 1 No. 1 |
31 |
Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets |
Vol. 1 No. 1 |
60 |
 |
|
|
GERIATRICS RELATED ARTICLES |
Title (Click for Details) |
Vol/Issue |
Page |
Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested |
Vol. 24 No. 5 |
408 |
Suspensions as a Valuable Alternative to Extemporaneously Compounded Capsules |
Vol. 21 No. 2 |
171 |
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review |
Vol. 19 No. 1 |
6 |
Treatment Options for Male Hypogonadism |
Vol. 17 No. 1 |
28 |
Testosterone Levels in an Aging Population: Screen, Measure, and Restore |
Vol. 15 No. 2 |
102 |
Clozapine 20-mg/mL Oral Suspension |
Vol. 14 No. 3 |
243 |
PreScription: The Ages of Man |
Vol. 14 No. 2 |
92 |
Emerging Evidence for Androgen Replacement Therapy in Aging Men |
Vol. 14 No. 2 |
94 |
PreScription: Geriatric Compounding: An Opportunity for Pharmacists |
Vol. 13 No. 6 |
492 |
Low Testosterone in Older Men: A Discussion and Review of Literature on Health Consequences of Hypogonadism in the Aging Male |
Vol. 13 No. 6 |
494 |
Compliance to Treatment in Elderly Dysphagic Patients: Potential Benefits of Alternate Dosage Forms |
Vol. 13 No. 6 |
498 |
Marketing the Geriatric Patient |
Vol. 13 No. 6 |
538 |
Calculations |
Vol. 13 No. 6 |
545 |
Selegiline Hydrochloride 1-mg/0.05-mL Oral Suspension in Oil |
Vol. 13 No. 4 |
340 |
Arthritis Epidemiology Impacts Pharmacists |
Vol. 12 No. 6 |
476 |
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration |
Vol. 12 No. 1 |
8 |
Calculations |
Vol. 11 No. 1 |
68 |
Carbidopa 1.25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
70 |
Clonidine Hydrochloride 0.1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
71 |
Methyldopa 25-mg/mL Oral Liquid |
Vol. 11 No. 1 |
75 |
Metolazone 1-mg/mL Oral Liquid |
Vol. 11 No. 1 |
76 |
Propranolol Hydrochloride 1-mg/mL Oral Liquid |
Vol. 10 No. 4 |
304 |
Stability of an Extemporaneously Compounded Propylthiouracil Suspension |
Vol. 9 No. 1 |
82 |
Book and Literature Reviews |
Vol. 8 No. 4 |
244 |
Case Report: Wound Care of a Diabetic Foot Ulcer |
Vol. 8 No. 4 |
265 |
Current Topical Treatments in Wound Healing - Part 1 |
Vol. 8 No. 4 |
269 |
Atropine 1-mg Gelatin Troches |
Vol. 8 No. 3 |
184 |
Clonidine HCl 0.2%/Gabapentin 6%/Ketamine HCl 10% in Pluronic Lecithin Organogel (PLO) |
Vol. 8 No. 3 |
185 |
Pain Management in the Elderly |
Vol. 8 No. 3 |
187 |
Amiodarone HCl 5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
214 |
Atenolol 2-mg/mL Oral Liquid |
Vol. 8 No. 3 |
215 |
Glycopyrrolate 0.5-mg/mL Oral Liquid |
Vol. 8 No. 3 |
218 |
Flucytosine 10-mg/mL Oral Liquid |
Vol. 8 No. 2 |
134 |
Griseofulvin 25-mg/mL Oral Liquid |
Vol. 8 No. 2 |
135 |
Stomatitis Mouthwash |
Vol. 8 No. 2 |
140 |
Tacrolimus 0.5-mg/mL Oral Liquid |
Vol. 8 No. 2 |
141 |
Tiagabine 1-mg/mL Oral Liquid |
Vol. 8 No. 2 |
142 |
Extemporaneous Formulation and Stability Testing of Mexiletine HCl Solution |
Vol. 8 No. 2 |
147 |
Ergoloid Mesylate 1-mg/mL Oral Liquid |
Vol. 7 No. 6 |
470 |
Perphenazine 2.5-mg/5-mL Syrup |
Vol. 7 No. 6 |
473 |
Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
Levofloxacin 250-mg/5mL Oral Liquid |
Vol. 7 No. 1 |
60 |
Ofloxacin 250-mg/5-mL Oral Liquid |
Vol. 7 No. 1 |
60 |
Erythromycin 400-mg/mL and Rifampin 50-mg/mL Oral Liquid |
Vol. 6 No. 5 |
367 |
Compounding for Geriatrics Patients |
Vol. 6 No. 3 |
168 |
Estrogen Replacement Therapy in the Treatment of Alzheimer's Disease |
Vol. 6 No. 3 |
171 |
Book Reviews: Wellness, Nutrition and Geriatrics |
Vol. 6 No. 3 |
180 |
Carbidopa 2-mg/mL and Levodopa 250-mg/mL Oral Suspension |
Vol. 6 No. 3 |
202 |
Mild Laxative |
Vol. 6 No. 3 |
185 |
Liver Pills for All Obstructions of the Liver, Gall Ducts, and Bowel |
Vol. 6 No. 3 |
185 |
Bioidentical Hormones in the Treatment of Osteoporosis |
Vol. 5 No. 5 |
339 |
Basics of Compounding: Suspensions |
Vol. 5 No. 4 |
294 |
Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Sugar-Free Suspension Structured Vehicle, USP |
Vol. 5 No. 4 |
296 |
Spironolactone Oral Suspension 2-mg/mL |
Vol. 5 No. 4 |
297 |
Progesterone Oral Suspension 40-mg/mL |
Vol. 5 No. 4 |
297 |
Xanthan Gum Oral Suspension Vehicle 0.3% |
Vol. 5 No. 4 |
297 |
The Basics of Compounding Emulsions, Part 2 |
Vol. 5 No. 3 |
198 |
The Basics of Compounding Emulsions, Part 1 |
Vol. 5 No. 2 |
120 |
Electrolyte and Rehydration Powder for Solution-Example of Powder Formulations |
Vol. 5 No. 1 |
38 |
Milk of Magnesia Concentrate, Unflavored |
Vol. 5 No. 1 |
47 |
Nicotinamide-Adenine Dinucleotide (NADH) in Parkinson's Disease and Alzheimer's Disease |
Vol. 4 No. 4 |
276 |
Amphotericin B 100-mg Troches |
Vol. 4 No. 3 |
208 |
Saliva Substitute for Dry Mouth/Throat |
Vol. 4 No. 3 |
215 |
Basics of Compounding: Compounding Solutions |
Vol. 4 No. 2 |
122 |
Osteoarthritis: Other Options |
Vol. 3 No. 6 |
433 |
Methotrexate 2.5-mg/5-mL Oral Liquid |
Vol. 3 No. 6 |
474 |
Alternatives for the Lactose-Intolerant Patient |
Vol. 2 No. 6 |
412 |
Treatment of Skin Aging with Topical Estrogens |
Vol. 2 No. 4 |
270 |
Stability of Ciprofloxacin in Extemporaneous Oral Liquid Dosage Form |
Vol. 2 No. 4 |
314 |
Vehicles for Compounding Oral Liquids: Some Practical Considerations |
Vol. 2 No. 2 |
160 |
Estrogen in the Treatment and Prevention of Alzheimer's Disease |
Vol. 2 No. 1 |
24 |
Ketoconazole 20-mg/mL Oral Liquid |
Vol. 1 No. 6 |
414 |
Baclofen 10-mg/mL Oral Liquid |
Vol. 1 No. 5 |
321 |
Captopril 0.75-mg/mL Oral Liquid |
Vol. 1 No. 5 |
322 |
Diltiazem HCl 12-mg/mL Oral Suspension |
Vol. 1 No. 5 |
323 |
Metolazone 1-mg/mL Oral Suspension |
Vol. 1 No. 5 |
329 |
Stability of Bethanechol Chloride Oral Liquid Dosage Forms |
Vol. 1 No. 4 |
278 |
Creative Compounding for the Geriatric Patient |
Vol. 1 No. 3 |
147 |
Drug Products and Drug Packaging for the Elderly |
Vol. 1 No. 3 |
150 |
Common Diseases of the Elderly |
Vol. 1 No. 3 |
152 |
Allopurinol 20-mg/mL Oral Liquid |
Vol. 1 No. 3 |
174 |
Dipyridamole 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
176 |
Labetalol HCl 40-mg/mL Oral Liquid |
Vol. 1 No. 3 |
179 |
Metoprolol Tartrate 10-mg/mL Oral Liquid |
Vol. 1 No. 3 |
180 |
Spironolactone 5-mg/mL with Hydrochlorothiazide 5-mg/mL Oral Liquid |
Vol. 1 No. 3 |
183 |
Spironolactone 25-mg/mL Oral Liquid |
Vol. 1 No. 3 |
184 |
Verapamil HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 3 |
188 |
Metronidazole 15-mg/mL Suspension |
Vol. 1 No. 3 |
202 |
Acetazolamide 25-mg/mL Oral Liquid |
Vol. 1 No. 2 |
101 |
Azathioprine 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
102 |
Flecainide Acetate 20-mg/mL Oral Liquid |
Vol. 1 No. 2 |
103 |
Methylcellulose 1% to 5% Solutions |
Vol. 1 No. 2 |
104 |
Methylcellulose Oral-Liquid Vehicles |
Vol. 1 No. 2 |
105 |
Procainamide HCl 50-mg/mL Oral Liquid |
Vol. 1 No. 2 |
110 |
Syrup NF |
Vol. 1 No. 2 |
111 |
Tetracaine 20-mg Lollipops |
Vol. 1 No. 2 |
112 |
Tetracycline Compound Troche |
Vol. 1 No. 2 |
113 |
Xanthan Gum Suspension Vehicle (0.2% to 0.5%) |
Vol. 1 No. 2 |
114 |
Stability of Allopurinol Suspension Compounded from Tablets |
Vol. 1 No. 2 |
128 |
Hospice Care and the Pharmacist |
Vol. 1 No. 1 |
11 |
Omeprazole (Prilosec) in the Atypical Patient, Administration of |
Vol. 1 No. 1 |
13 |
Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets |
Vol. 1 No. 1 |
60 |